Antiplatelet effect of a newly developed AMP-activated protein kinase activator YLF-466D

European Journal of Pharmacology

Volumn 760, Issue , 2015, Pages 81-87

  Liu, Yingqiu ^a   Park, Jung Min ^a   Oh, Seok Jeong ^a   Chang, Kyung Hwa ^a   Lee, Moo Yeol ^a  

^a Dongguk University   (South Korea)

Author keywords

Aggregation; AMP activated protein kinase; Antiplatelet agents; Platelets; YLF 466D

Indexed keywords

3-((3-((4-CHLOROPHENYL)PHENYLMETHYLENE)-2,3-DIHYDRO-2-OXO-1H-INDOL-1-YL)METHYL)BENZOIC ACID; ANTITHROMBOCYTIC AGENT; BENZOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDOLE DERIVATIVE;

ANIMAL; CHEMISTRY; DRUG EFFECTS; MALE; METABOLISM; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; THROMBOCYTE AGGREGATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BENZOATES; INDOLES; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84928778551     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.03.084     Document Type: Article

References (22)

1. A. Aszodi, A. Pfeifer, M. Ahmad, M. Glauner, X.H. Zhou, L. Ny, K.E. Andersson, B. Kehrel, S. Offermanns, and R. Fassler The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function EMBO J. 18 1999 37 48
2. S.B. Brown, M.C. Clarke, L. Magowan, H. Sanderson, and J. Savill Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program J. Biol. Chem. 275 2000 5987 5996
3. Z.P. Chen, K.I. Mitchelhill, B.J. Michell, D. Stapleton, I. Rodriguez-Crespo, L.A. Witters, D.A. Power, P.R. Ortiz de Montellano, and B.E. Kemp AMP-activated protein kinase phosphorylation of endothelial NO synthase FEBS Lett. 443 1999 285 289
4. B. Cool, B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H.S. Camp, and E. Frevert Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome Cell Metab. 3 2006 403 416
5. M.A. Ewart, and S. Kennedy Diabetic cardiovascular disease - AMP-activated protein kinase (AMPK) as a therapeutic target Cardiovasc. Hematol. Agents Med. Chem. 10 2012 190 211
6. I. Fleming, C. Schulz, B. Fichtlscherer, B.E. Kemp, B. Fisslthaler, and R. Busse AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets Thromb. Haemost. 90 2003 863 871
7. S.H. Francis, J.L. Busch, J.D. Corbin, and D. Sibley cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action Pharmacol. Rev. 62 2010 525 563
8. J.E. Freedman, J. Loscalzo, M.R. Barnard, C. Alpert, J.F. Keaney, and A.D. Michelson Nitric oxide released from activated platelets inhibits platelet recruitment J. Clin. Invest. 100 1997 350 356
9. P. Gresele, S. Momi, and E. Falcinelli Anti-platelet therapy: phosphodiesterase inhibitors Br J. Clin. Pharmacol. 72 2011 634 646
10. M. Halbrugge, and U. Walter Purification of a vasodilator-regulated phosphoprotein from human platelets Eur. J. Biochem. 185 1989 41 50
11. D.G. Hardie AMP-activated protein kinase as a drug target Annu. Rev. Pharmacol. Toxicol. 47 2007 185 210
12. N. Henin, M.F. Vincent, and G. Van den Berghe Stimulation of rat liver AMP-activated protein kinase by AMP analogues Biochim. Biophys. Acta 1290 1996 197 203
13. Y.Y. Li, L.F. Yu, L.N. Zhang, B.Y. Qiu, M.B. Su, F. Wu, D.K. Chen, T. Pang, M. Gu, W. Zhang, W.P. Ma, H.W. Jiang, J.Y. Li, F.J. Nan, and J. Li Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice Toxicol. Appl. Pharmacol. 273 2013 325 334
14. Y. Liu, S.J. Oh, K.H. Chang, Y.G. Kim, and M.Y. Lee Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole Biochem. Pharmacol. 86 2013 914 925
15. A.D. Michelson Antiplatelet therapies for the treatment of cardiovascular disease Nat. Rev. Drug. Discov. 9 2010 154 169
16. N. Musi, T. Hayashi, N. Fujii, M.F. Hirshman, L.A. Witters, and L.J. Goodyear AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle Am. J. Physiol. Endocrinol. Metab. 280 2001 E677 E684
17. T. Pang, Z.S. Zhang, M. Gu, B.Y. Qiu, L.F. Yu, P.R. Cao, W. Shao, M.B. Su, J.Y. Li, F.J. Nan, and J. Li Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells J. Biol. Chem. 283 2008 16051 16060
18. V. Randriamboavonjy, and I. Fleming Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol. Rep. 57 Suppl 2005 59 65
19. A. Smolenski, W. Poller, U. Walter, and S.M. Lohmann Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I J. Biol. Chem. 275 2000 25723 25732
20. G.R. Steinberg, and B.E. Kemp AMPK in health and disease Physiol. Rev. 89 2009 1025 1078
21. L.F. Yu, Y.Y. Li, M.B. Su, M. Zhang, W. Zhang, L.N. Zhang, T. Pang, R.T. Zhang, B. Liu, J.Y. Li, J. Li, and F.J. Nan Development of novel alkene oxindole derivatives as orally efficacious AMP-activated protein kinase activators ACS Med. Chem. Lett. 4 2013 475 480
22. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, and D.E. Moller Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 108 2001 1167 1174